Figure 1. Estimated Probability Of Achieving Initial Headache Response Within 4 Hours Of Treatment In Pooled Trials 1, 2, And 3a (Sumatriptan Fig1)
Sumatriptan Tablet
Product Images NDC 68788-6778
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Sumatriptan (NDC 68788-6778). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 2. The Estimated Probability Of Patients Taking A Second Dose Of Sumatriptan Tablets Or Other Medication To Treat Migraine Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Trials 1, 2, And 3a (Sumatriptan Fig2)
Sumatriptan Succinate Tablets 100mg (Sumatriptan Fig5)
This text appears to be a medication label for Sumatriptan Succinate Tablets, manufactured by Aurobindo Pharma Limited. Each tablet contains 100mg of Sumatriptan succinate. The label also contains cautionary information, however, the quality of is poor and the complete message is not readable.*
Chemical Structure (Sumatriptan Str)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
